Financings in Brief: Intuitive Surgical
This article was originally published in The Gray Sheet
Executive Summary
Intuitive Surgical: Raises $17 mil. in a private placement, bringing to $47 mil. the amount the Mountain View, California-based R&D firm has raised since the beginning of 1997. U.S. clinical trials of Intuitive's tele-robotic instrumentation system in minimally invasive surgery will begin in the second quarter of 1998, Lonnie Smith, president and CEO, reports at a Dec. 2 session of the BancAmerica Robertson Stephens conference in New York City ("The Gray Sheet" Dec. 8, In Brief). The device's three components include a surgeon's control console with 3D visual display, mechanical instrument manipulators positioned over the patient, and surgical instruments designed for use through small (1 cm) incisions. Intuitive plans initially to pursue cardiac surgery indications. The recent financing "will support Intuitive as it transitions from research and development to manufacturing, sales and marketing" of the system, the company says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.